ClinVar Miner

Submissions for variant NM_000249.3(MLH1):c.1128T>C (p.Asp376=) (rs267607824)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000075113 SCV000106105 no known pathogenicity Lynch syndrome 2013-09-05 reviewed by expert panel research MAF >1%
Invitae RCV001080774 SCV000259719 benign Hereditary nonpolyposis colorectal neoplasms 2020-10-27 criteria provided, single submitter clinical testing
Counsyl RCV000410805 SCV000488560 likely benign Lynch syndrome II 2016-04-28 criteria provided, single submitter clinical testing
GeneDx RCV000442515 SCV000513623 benign not specified 2015-07-15 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Ambry Genetics RCV000569167 SCV000669527 likely benign Hereditary cancer-predisposing syndrome 2015-02-19 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Color Health, Inc RCV000569167 SCV000684716 likely benign Hereditary cancer-predisposing syndrome 2016-03-30 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000759078 SCV000888172 benign not provided 2018-05-23 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000442515 SCV000917643 benign not specified 2018-04-13 criteria provided, single submitter clinical testing Variant summary: MLH1 c.1128T>C alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 1.55 fold of the estimated maximal expected allele frequency for a pathogenic variant in MLH1 causing Lynch Syndrome phenotype (0.00071), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.1128T>C has been reported in the literature in individuals affected with Lynch Syndrome, however 9 out of the reported 18 families with c.1128T>C (Asp376) also had pathogenic mutations in MLH1, MSH2 or MSH6 (Shin_2004), strongly supporting the benign nature of this variant. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000759078 SCV001548738 likely benign not provided no assertion criteria provided clinical testing MLH1, EXON 12, c.1128T>C, p.Asp376=, Heterozygous, Likely benign The MLH1 p.Asp376= variant was identified in 18 of 282 proband chromosomes (frequency: 0.06) from individuals or families with Lynch syndrome and was present in 12 of 368 control chromosomes (frequency: 0.03) from healthy individuals (Shin 2004). The variant was also identified in the following databases: dbSNP (ID: rs267607824) as "With Likely benign allele", ClinVar (3x likely benign, 3x benign including review by expert panel InSiGHT), Clinvitae, Mismatch Repair Genes Variant Database, and the Insight Hereditary Tumors Database (1x, not pathogenic). The variant was not identified in GeneInsight-COGR, Cosmic, MutDB, UMD-LSDB, or the Zhejiang Colon Cancer Database. The variant was identified in control databases in 20 of 276984 chromosomes at a frequency of 0.00007 (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include East Asian in 20 of 18854 chromosomes (freq: 0.001), while the variant was not observed in the African, Other, Latino, European, Ashkenazi Jewish, Finnish, and South Asian populations. A study by Shin 2004 found no statistically significant difference in frequency between Lynch syndrome patients and controls for this variant, and listed it as a polymorphism. The p.Asp376= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.